Therapicon® strong background and dedication in the pharmaceutical research field is mainly summarized in the listed proprietary technology.
During the most recent years Therapicon has boosted significant targets especially in advanced market segments of osteoporosis and immunology, while important energies are also dedicated to advanced segments of oncology (MF-kappaB modifiers) and virology (neuraminidase and protein M2 inhibitors).
A sophisticated technology for the intranasal delivery of peptides and of other drugs as well is our main expertise. New technology for the topical delivery of many known drugs has been also achieved through an inert pressurized delivery system (EasysprayR).
A considerable increase of personnel (technicians and skilled workers) is forecast during the next years, in order to meet the market demand of the exclusive products under development.
Abstracts of the leading patent applications (most of them already granted or at final stage of granting) are listed here below for guidance of our technical expertise:
Therapicon® is a registered trade-mark in Italy and at OMPI (WIPO)-Geneva